Lapixen (Lacidipine)

Lacidipine selectively blocks L-type calcium channels in the smooth muscle of blood vessels. This blockade prevents calcium entry, causing the vessels to relax and widen (vasodilation), which decreases peripheral resistance and ultimately lowers arterial blood pressure.

The appropriate dose of Lapixen is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lacidipine in pregnancy and lactation are limited. It is generally recommended to avoid use unless the potential benefit justifies the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Lapixen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacidipine belongs to the dihydropyridine class of calcium channel blockers, offering potent vasodilation with a relatively long half‑life. Compared with agents such as amlodipine, it may provide a smoother blood‑pressure profile but shares similar side‑effect patterns. Choice of therapy depends on patient‑specific factors and physician judgment.

Lapixen tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Lapixen is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, angioedema, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, or signs of liver dysfunction such as jaundice.

Lacidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. Caution is advised for individuals with severe aortic stenosis, unstable angina, or those taking strong CYP3A4 inhibitors without medical supervision.